Cristhiam M. Rojas Hernandez, M.D.
Department of Pulmonary Medicine, Division of Internal Medicine
About Dr. Cristhiam M. Rojas Hernandez
Dr. Rojas Hernandez is a valedictorian graduate of the Medical School at the Universidad del Valle in Cali, Colombia. He completed an internship and residency in Internal Medicine at Yale University (Bridgeport Hospital program) where he received several awards on professionalism and medical education. Subsequently he trained as a Hematologist and Oncologist at the University of New Mexico Comprehensive Cancer Center. During his fellowship he received recognition as the Laurent T. Visconti Fellow of the Year in 2014.
Having joined MD Anderson in 2014, Rojas Hernandez served as the University of Texas/Mc Govern Medical School site director for the clinical rotation in Hematology & Oncology at MD Anderson Cancer Center between 2017-2025. For his work in the education field, he received the Cheves M. and Isabella C. Smythe Endowed Award for Excellence in Resident Education. Additionally, he was named the Faculty Teacher of the year in 2016 by the Hematology and Oncology fellowship program, and the Faculty Educator of the month of April 2018 at MD Anderson Cancer Center.
Dr. Rojas-Hernandez has research interest in thrombosis and hemostasis. He has participated in pivotal multicenter studies of cancer associated thrombosis and led a multicenter international study focused quality of life and treatment adherence to anticoagulation in cancer patients (https://clinicaltrials.gov/ct2/show/NCT03407469).
Dr. Rojas-Hernandez has developed an international reputation in the field of Cancer Associated Thrombosis; he has participated as speaker in multiple meetings of the International Society of Thrombosis and Haemostasis, the International Conference on Thrombosis and Hemostasis Issues in Cancer, The Society of Vascular Medicine, The Multinational Association of Supportive Care in Cancer, the Colombian Society of Cardiology and Cardiovascular Surgery (SCC) and the Colombian Association of Palliative Care (ASOCUPAC). In 2024, Dr. Rojas-Hernandez joined the NCCN Cancer-Associated Venous Thromboembolic Disease Panel as a representative of the University of Texas MD Anderson Cancer Center.
Dr. Rojas-Hernandez also serves as faculty in the MD Anderson Immuno-Oncologic Toxicity Initiative (MDACC IOTOX). He is a contributor of the MDACC IOTOX guidelines and invited author of several publications and textbook chapters on the topic of hematologic complications of immune check point inhibitors.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Pulmonary, Section Benign Hematology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Pulmonary Medicine, Section Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2005 | Universidad del Valle, Cali, Colombia, Medical School, MD |
Postgraduate Training
| 2011-2014 | Clinical Fellowship, Hematology and Oncology, The University of New Mexico Health Sciences Center, Albuquerque, New Mexico |
| 2008-2011 | Clinical Residency, Internal Medicine, Yale University (Bridgeport Hospital), Bridgeport, Connecticut |
Licenses & Certifications
| 2025 | Oklahoma State Board of Medical Licensure |
| 2025 | Arizona Medical Board |
| 2024 | Washington State Department of Health |
| 2024 | Mississippi State Board of Medical Licensure |
| 2023 | Georgia Composite Medical Board |
| 2023 | Tennessee Board of Medical Examiners |
| 2023 | Louisiana Physician and Surgeon License Interstate Medical Licensure Compact |
| 2023 | Alabama Board of Medical Examiners |
| 2021 | Florida Board of Medicine |
| 2014 | American Board of Internal Medicine - Hematology |
| 2014 | American Board of Internal Medicine - Medical Oncology |
| 2014 | Texas Medical Board |
| 2011 | American Board of Internal Medicine |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2020
Administrative Appointments/Responsibilities
The University of Texas Site Director for the Hematology and Oncology Clinical Rotation, Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2025
Other Professional Positions
Senator, Faculty Senate MD Anderson Cancer Center, Houston, TX, 2019 - 2025
Intramural Institutional Committee Activities
Member, Identifying pRe-Operative anemia (IRON) initiative, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Anticoagulation Stewardship Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Department of Internal Medicine Education Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2025
Member, DoIM Immune Oncology Toxicity Working Group, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, DoIM Research Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2022
Member, Pharmacy and Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Member, Venous Thromboembolism Working Group, The University of Texas MD Anderson Cancer Center, 2015 - Present
Member, DoIM Quality Council, The University of Texas MD Anderson Cancer Center, 2015 - 2018
Editorial Activities
Associate Editor, Practice Update, 2017 - 2020
Honors & Awards
| 2022 | 2022 Outstanding Study Group Award: Hemostasis Study Group, The Multinational Association of Supportive Care in Cancer |
| 2018 | Faculty Educator of the Month-April 2018, The University of Texas MD Anderson Cancer Center |
| 2017 | Top Rated Poster: Outcomes of Subsegmental Pulmonary Embolism (SSPE) in Cancer Population, XXVI Congress of the International Society on Thrombosis and Haemostasis |
| 2016 | 2016 Teacher of the Year for the Hematology Oncology Fellowship Program, Division of Cancer Medicine at MD Anderson Cancer Center |
| 2016 | Cheves M. and Isabella C. Smythe Endowment Award for Excellence in Resident Education, The University of Texas in Houston Department of Internal Medicine |
| 2015 | Eberhard Mammen Seminars in Thrombosis and Haemostasis 2015 Most Popular Article Awards for Open Access Category, Seminars in Thrombosis and Haemostasis |
| 2014 | The Laurent T. Visconti Teaching Fellow of the Year, The University of New Mexico Health Sciences Center |
| 2011 | The American Cancer Society Resident Screening Award, The American Cancer Society |
| 2011 | The Raymond Haddad, MD Award for Outstanding Professionalism, Yale University (Bridgeport Hospital) |
| 2010 | The Director's Award for Outstanding Teaching, Yale University (Bridgeport Hospital) |
| 2005 | The Exemplary Physician Award, Universidad del Valle School of Medicine |
| 2005 | Valedictorian Award, Universidad del Valle School of Medicine |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Venous Thromboembolism in Oncologic Patients. Invited. APRN Fellowship Lecture Series. Houston, Texas, US.
- 2024. Advances in Prevention and Treatment of Cancer Associated Venous Thrombosis. Division of Hematology Oncology Grand Rounds. Albuquerque, New Mexico, US.
- 2023. Hematological Immune Related Adverse Events. 2023 IOTOX Clinical Education Symposium. Houston, TX, US.
- 2023. Decreasing the Incidence of Inappropriate Anticoagulation Administration in Patients with Thrombocytopenia. Invited. Houston, TX, US.
- 2023. Immune Checkpoint Hemolytic Anemia. Houston, TX, US.
- 2023. Diagnosis and Approach to Immune Hemolytic Anemia. Houston, TX, US.
- 2022. Characterization of Coagulopathy and Outcomes in Cancer Patients with Severe COVID-19 Illness: Longitudinal Changes in Hospitalized Cancer Patients. Houston, TX, US.
- 2022. Hematologic Complications of Immune Check Point Inhibitors. Houston, TX, US.
- 2021. Erythrocytosis. Leukemia Grand Rounds. Houtson, TX, US.
- 2021. COVID, Coagulopathy, and Thrombosis. Houston, TX, US.
- 2021. Immune Check Point Inhibitor Toxicity and Hematology. Houston, TX, US.
- 2021. Heparin Induced Thrombocytopenia. Houston, TX, US.
- 2020. Characteristics and Clinical Outcomes of Coagulopathy in Cancer Patients with COVID19. Ken Kennedy Data Science Conference. Houston, TX, US.
- 2020. Updates on the Use of Oral Anticoagulants in Cancer Population. Houston, TX, US.
- 2020. Updates on the Management of Venous Thromboembolism in Cancer Population: From Outpatient Prophylaxis to Treatment in Advanced Cancer. Houston, TX, US.
- 2020. The Latest in Anticoagulation in Cancer Patients. 2020 Oncologic Emergency Medicine Conference. Houston, TX, US.
- 2020. A 41-year-old Man with a Four-Year History of Erythrocytosis: A Common Presentation of an Extremely Rare Disease. Houston, TX, US.
- 2019. Updates on the Management of Cancer Associated Thrombosis. Invited. Houston, TX, US.
- 2019. Strategies for Anticoagulation Reversal for Direct Oral Anticoagulants. Society of Critical Care Medicine (SCCM) Texas Chapter - 8th Annual symposium. Houston, TX, US.
- 2019. Management of Anticoagulation in Challenging Scenarios of Cancer Associated Thrombosis. Houston, TX, US.
- 2019. Management of Cancer-Associated Thrombosis. Houston, TX, US.
- 2018. Measurement of Adherence and Health-related Quality of Life in Cancer-related Venous Thromboembolism: Update. Houston, TX, US.
- 2018. New Developments in Treating Cancer Associated Venous Thromboembolism. Houston, TX, US.
- 2017. Measurement of Adherence and Health-related Quality of Life in Cancer-related Venous Thromboembolism. Houston, TX, US.
- 2017. Dealing with Bleeding and Clotting at the Same Time- Management Dilemmas in Anticoagulation. Houston, TX, US.
- 2016. Challenging Case Conference: Platelet Refractoriness. Houston, TX, US.
- 2015. Venous Thromboembolism (VTE) Diagnosis and Management in Cancer Patients. Houston, TX, US.
National Presentations
- 2024. Year in Review: Venous Thromboembolism. Invited. Vascular Scientific Sessions 2024. Houston, TX, US.
- 2021. Cancer Associated Thrombosis (CAT) in COVID-19 Era. The Multinational Association of Supportive Care in Cancer, US.
- 2019. Anticoagulation for Venous Thromboembolism in Special Populations (Obesity, Underweight, Pregnancy, Renal Failure). San Francisco, CA, US.
- 2017. Update on Direct Oral Anticoagulants in Cancer. Washington, MD, US.
International Presentations
- 2023. Hematologic Complications of Immune Checkpoint Inhibitors. Invited. The Multinational Association of Supportive Care in Cancer. Nara, JP.
- 2022. Medicion de la Adherencia y la Calidad de Vida Relacionada con la Salud Durante la Terapia Anticoagulante en la Tromboembolia Venosa Asociada al Cancer: Un Estudio Cuantitativo Multicentrico. San Jose, CR.
- 2022. Calidad de Vida Durante Anticoagulacion a Largo Plazo. XV Congreso Internacional de Cardiologia. Cali, CO.
- 2022. Measurement of Adherence and Health-Related Quality of Life During Anticoagulation Therapy in Cancer Associated-Venous Thromboembolism. Toronto (virtually), CA.
- 2021. Anticoagulation and Brain Metastasis, Thrombocytopenia and Use of DOAC. Hemato Oncologos Instituto de Oncologia. Cali, CO.
- 2019. Redes de Colaboracion Internacional para Investigacion. Cali, CO.
- 2019. Integrando los Cuidados Paliativos en Trombosis Asociada a Cancer en Adultos. Cali, CO.
- 2018. Measurement of Health-related Quality of Life, Adherence and Health-care Resource Utilization during Anticoagulation Therapy in Cancer-related Venous Thromboembolism. Vienna, AT.
- 2017. Venous Thromboembolism in Acute Leukemia: Improved Survival with Anticoagulation. Berlin, DE.
- 2016. Safe and Effective Use of Direct Oral Anticoagulants (DOAC) Versus Conventional Anticoagulation for the Treatment of Cancer-Related Venous Thromboembolism. Bergamo, IT.
Formal Peers
- 2022. Thromboprophylaxis and Venous Thromboembolism (VTE) Management in Hematopoietic Stem Cell Transplant (HSCT) Patients. Visiting. Albuquerque (virtually), NM, US.
- 2020. Anticoagulation in Challenging Scenarios of Cancer Associated Thrombosis. Visiting. Cali, CO.
- 2020. Approach to Anemia and Hemolysis. Visiting. Houston, TX, US.
- 2020. Approach to Venous Thrombosis in Cancer. Visiting. Cali, CO.
- 2019. Approach to Thrombophilia in Adult Population. Visiting. Houston, TX, US.
- 2018. What Role Does Direct Oral Anticoagulation (DOAC) Therapy Play in Treatment of Cancer Associated Venous Thromboembolism?. Visiting. Houston, TX, US.
- 2011. Autoimmune Hemolytic Anemias. Visiting. Houston, TX, US.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | A Phase 1/2, Dose-Finding Study Investigating The Safety And Efficacy Of Pirtobrutinib In Adults With Immune Thrombocytopenia |
| Funding Source: | Eli Lilly |
| Role: | PI |
| ID: | 2025-0416 (J2N-MC-JZNZ) |
| Date: | 2024 - Present |
| Title: | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with a Safety and Dose Confirmation Run-in Period, to Evaluate the Efficacy and Safety of Obexelimab in Patients with Warm Autoimmune Hemolytic Anemia (SApHAire) |
| Funding Source: | Zenas Biopharma |
| Role: | PI |
| ID: | 2024-0179 |
| Date: | 2022 - 2024 |
| Title: | A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER) |
| Funding Source: | ANTHOS therapeutics |
| Role: | Principal Investigator-MDACC |
| ID: | CTA 2021-0981 |
| Date: | 2020 - 2022 |
| Title: | An Open-Label, Randomized, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study) |
| Funding Source: | Aspen Global Incorporated |
| Role: | PI |
| ID: | ERGCR-18-ORGHIT-001 |
| Date: | 2015 - 2017 |
| Title: | A Phase 3B, Prospective, Randomized, Open-label, Blind evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban versus Dalteparin in Venous Thromboembolism Associated with Cancer (HOKUSAI CANCER VTE trial) |
| Funding Source: | Daichii Sankyo |
| Role: | PI |
| ID: | CS2016-13015460-AM1-LK |
Selected Publications
Peer-Reviewed Articles
- Pinto FG, Voltani DL, Rojas-Hernandez CM. Primary prophylaxis and treatment of venous thromboembolism in malignancy with focus on lung cancer: a review of current evidence. Curr Opin Pulm Med, 2026. e-Pub 2026. PMID: 41783954.
- Subramanian, N, Garcia Pleitez, H, Nguyen, D, Milton, D, Kebriaei, P, Shpall, E, Cheng, L, Lu, J, Jin, S, Wu, CC, Sheth, RA, Ferrajoli, A, Hanzelka, KM, Kroll, M, Rojas Hernandez, CM. Automated natural language processing to identify venous thromboembolism from diagnostic imaging reports. Blood Vessels, Thrombosis and Hemostasis 3(1), 2026. e-Pub 2026.
- Subramanian N, Garcia Pleitez H, Nguyen D, Milton DR, Kebriaei P, Shpall E, Cheng L, Lu J, Jin S, Wu CC, Sheth RA, Ferrajoli A, Toale KM, Kroll MH, Rojas-Hernandez CM. Automated natural language processing to identify venous thromboembolism from diagnostic imaging reports. Blood Vessel Thromb Hemost 3(1):100122, 2026. e-Pub 2026. PMID: 41503124.
- Venkatesh N, Milligan K, Parrish J, Qing Y, Sun R, Strati P, Ramdial J, Ayers A, Ahmed S, Hernandez CR. Venous Thromboembolism in Aggressive B-Cell Lymphoma Patients Treated with CD19 CAR-T Therapy: Single-Institution Study. EJHaem 7(1):e70227, 2026. e-Pub 2026. PMID: 41623548.
- Subramanian NG, Aung FM, Hunzeker ZE, Patel KK, Lee HC, Jin S, Young E, Bassett RL Jr, Rojas Hernandez CM. Clinical factors associated with venous thromboembolism in multiple myeloma patients treated with daratumumab. Discov Med (Singap) 3(1):15, 2026. e-Pub 2026. PMID: 41743685.
- Glombicki SE, Matin SF, Muzzafar T, Etchegaray M, Dailey Garnes, NJ, Rojas Hernandez CM. Acquired thrombocytopenia and neutropenia after intrarenal BCG immunotherapy treatment for urothelial carcinoma of the kidney: a case report. Discover Medicine 2(1):179, 2025. e-Pub 2025.
- Streiff, MB, Holmstrom, B, Angelini, D, Ashrani, A, Buckner, T, Diep, R, Fertrin, KY, Fogerty, AE, Crestani, NG, Gangaraju, R, Rojas Hernandez, CM, Goldhaber, SZ, Ibrahim, I, Kubal, T, Leavitt, AD, Lim, M, Mann, J, Mantha, S, Morton, C, Nester, A, O’Brien, A, Ortel, TL, Pine, AB, Pishko, A, Ranade, M, Salmasi, A, Schaefer, J, Williams, E, Wool, GD, Wun, T, Montgomery, S, Nguyen, J, Freedman-Cass, DA, Sliker, B. Cancer-Associated Venous Thromboembolic Disease, Version 2.2024. JNCCN Journal of the National Comprehensive Cancer Network 22(7):483-506, 2024. e-Pub 2024. PMID: 39236759.
- Laganà, M, Brondani, VB, Herrera, KR, Chahla, BB, Yaylaci, F, Bassett Jr, R, Jimenez, C, Varghese, J, Waguespack, SG, Campbell, M, Shah, AY, Rojas Hernandez, CM, Habra, MA. Venous thromboembolism in adrenocortical carcinoma. Oncologist 29(7):575-580, 2024. e-Pub 2024. PMID: 38776552.
- Chamseddine, SM, Lapelusa, M, Carter, K, Nguyen, V, Mohamed, YI, Sakr, Y, Rojas Hernandez, CM, Hatia, RI, Hassan, MM, Goss, JA, Elsayes, KM, Rashid, A, Sun, R, Cao, HT, Amin, H, Kaseb, A. Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab. Journal of Gastrointestinal Oncology 15(3):1324-1330, 2024. e-Pub 2024. PMID: 38989410.
- Ma S, La J, Swinnerton KN, Guffey D, Bandyo R, De Las Pozas G, Hanzelka K, Xiao X, Rojas-Hernandez CM, Amos CI, Chitalia V, Ravid K, Merriman KW, Flowers CR, Fillmore N, Li A. Thrombosis Risk Prediction inLymphoma Patients: A Multi-Institutional, Retrospective Model Development and Validation Study. Am J Hematol, 2024. e-Pub 2024. PMID: 38654461.
- Lee S, Ross JA, Zalpour A, Henry JT, Rojas Hernandez CM. Management of DOAC Related Bleeding in Cancer Patients: A Single Center-Case Series. J Thromb Thrombolysis 57(4):677-682, 2024. e-Pub 2024. PMID: 38556578.
- Patel RM, Pal K, Ahmed SH, Kuban JD, Patel M, Shah K, Habibollahi P, Metwalli Z, Gurusamy V, Gupta S, Rojas-Hernandez CM, Afshar-Kharghan V, Kroll MH, Sheth RA. Mechanical Venous Thrombectomy for Deep Venous Thrombosis in Cancer Patients: A Single-Center Retrospective Study. Cardiovasc Intervent Radiol 47(5):556-566, 2024. e-Pub 2024. PMID: 38548981.
- Hopper, TA, Miranda, R, Sheth, RA, Rojas Hernandez, CM. Arterial Thromboembolism in a Patient With Cancer With Unclear Etiology. Annals of Internal Medicine Clinical Cases 3(10), 2024. e-Pub 2024.
- Ullah F, Song J, Rojas Hernandez CM, Kroll MH, Escalante CP, Toale KM. Safety and Effectiveness of Direct Oral Anticoagulants for the Treatment of Gastrointestinal Cancer-Associated Venous Thromboembolism. Oncologist 28(11):e1005-e1016, 2023. e-Pub 2023. PMID: 37310796.
- Lin J, Rodriguez-Martinez P, Oo TH, E S, Jorgensen J, Rojas-Hernandez CM. Durvalumab-induced Pure White Cell Aplasia. J Immunother 47(1):7-9, 2023. e-Pub 2023. PMID: 37904601.
- Font C, Gomez-Mesa JE, Lopez-Nunez JJ, Calderon C, Galindo-Coral S, Wu CC, Ma J, Kroll MH, Rojas-Hernandez CM. Measurement of Adherence and Health-related Quality of Life During Anticoagulation Therapy in Cancer-associated Venous Thromboembolism (VTE): A Multicenter Quantitative Study. Support Care Cancer 31(10):615, 2023. e-Pub 2023. PMID: 37801086.
- Avery J, Guffey D, Ma S, Basom R, Lee SJ, Garcia D, Rojas Hernandez CM, Li A, Martens KL. Risks Factors and Outcomes for Isolated Catheter-related Deep Venous Thrombosis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Thromb Res 229:1-6, 2023. e-Pub 2023. PMID: 37356171.
- Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b Study of Combined Selinexor and Eribulin for the Treatment of Advanced Solid Tumors and Triple-negative Breast Cancer. Cancer 129(14):2201-2213, 2023. e-Pub 2023. PMID: 37016732.
- Li A, De Las Pozas G, Andersen CR, Nze CC, Toale KM, Milner EM, Fillmore NR, Chiao EY, Rojas Hernandez C, Kroll MH, Merriman KW, Flowers CR. External Validation of a Novel Electronic Risk Score for Cancer-Associated Thrombosis in a Comprehensive Cancer Center. Am J Hematol 98(7):1052-1057, 2023. e-Pub 2023. PMID: 37067102.
- Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, Thomas SK, Hao D, Chu Y, Weber DM, Lin P, Lutter-Berka Z, Berrios Nolasco DA, Huang M, Bansal H, Song X, Zhang J, Futreal A, Moreno Rueda LY, Symer DE, Green MR, Rojas Hernandez CM, Kroll M, Afshar-Khargan V, Ndacayisaba LJ, Kuhn P, Neelapu SS, Orlowski RZ, Wang L, Manasanch EE. Single Cell Clonotypic and Transcriptional Evolution of Multiple Myeloma Precursor Disease. Cancer Cell 41(6):1032-1047.e4, 2023. e-Pub 2023. PMID: 37311413.
- Thein KZ, Elsaim SA, Ma MQ, Rojas-Hernandez CM, Elsayem A. Heparin-Induced Thrombocytopenia at the Emergency Department Due to Intermittent Heparin Flush in a Patient Undergoing Stem Cell Transplant. The Cureus Journal of Medical Science, 2022. e-Pub 2022.
- Thein KZ, Elsaim SA, Ma MQ, Rojas Hernandez CM, Elsayem A. Heparin-Induced Thrombocytopenia at the Emergency Department Due to Intermittent Heparin Flush in a Patient Undergoing Stem Cell Transplant. Cureus 14(11):e31798, 2022. e-Pub 2022. PMID: 36569714.
- Qdaisat A, Wechsler AH, Cruz Carreras MT, Menendez JR, Lipe D, Highsmith EA, Kamal M, Al-Breiki A, Rojas Hernandez CM, Wu CC, Yeung SJ. Concomitant Deep Vein Thrombosis in Cancer Patients with Unsuspected Pulmonary Embolism. Cancers (Basel) 14(18), 2022. e-Pub 2022. PMID: 36139673.
- Adimora I, Rojas Hernandez CM. Thrombotic Thrombocytopenic Purpura Triggered by Acute Myeloid Leukemia: A Case Report. Am J Case Rep 23:e935911, 2022. e-Pub 2022. PMID: 36039027.
- Kroll MH, Yee C, Rojas Hernandez CM. Hematologic Complications of Immune Checkpoint Inhibitors. Blood 139(25):3594-3604, 2022. e-Pub 2021. PMID: 34610113.
- Li A, Martens KL, Nguyen D, Basom R, Rondon G, Jin S, Young E, Amos CI, Lee SJ, Davis C, Garcia DA, Champlin R, Shpall E, Kebriaei P, Rojas Hernandez C. External Validation of the HIGH-2-LOW Model: A Predictive Score for Venous Thromboembolism after Allogeneic Transplant. Am J Hematol 97(6):740-748, 2022. e-Pub 2022. PMID: 35266218.
- Nelson BE, Ejezie CL, Stephen BA, Nardo M, Campbell E, Gong J, Hong DS, Fu S, Yap TA, Murphy MB, Piha-Paul S, Daver NG, Rojas-Hernandez CM, Naing A. Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. J Hematol 11(3):113-120, 2022. e-Pub 2022. PMID: 35837373.
- Barrios-Ruiz A, Davila-Gonzalez D, Fountain E, Cheng L, Verstovsek S, Rojas-Hernandez CM. Potential Limitations of Diagnostic Standard Codes to Distinguish Polycythemia Vera and Secondary Erythrocytosis. Sci Rep 12(1):4674, 2022. e-Pub 2022. PMID: 35304527.
- Qdaisat A, Yeung SJ, Rojas Hernandez CH, Samudrala P, Kamal M, Li Z, Wechsler AH. Characteristics and Outcomes of Intracranial Hemorrhage in Cancer Patients Visiting the Emergency Department. J Clin Med 11(3), 2022. e-Pub 2022. PMID: 35160096.
- Martens KL, Amos CI, Hernandez CR, Kebriaei P, da Costa WL, Basom R, Davis C, Kesten M, Carrier M, Garcia DA, Lee SJ, Li A. Impact of Anticoagulation on Recurrent Thrombosis and Bleeding After Hematopoietic Cell Transplantation. Am J Hematol 96(9):1137-1146, 2021. e-Pub 2021. PMID: 34097772.
- Abelhad NI, Qiao W, Garg N, Rojas-Hernandez CM. Thrombosis and Bleeding Outcomes in the Treatment of Cerebral Venous Thrombosis in Cancer. Thromb J 19(1):37, 2021. e-Pub 2021. PMID: 34074321.
- Goswamy RV, Wilson NR, Tannenbaum DJ, Aung FM, Hernandez CMR. Practice Patterns and Clinical Outcomes of Platelet Alloimmunization in a Comprehensive Cancer Center. Transfus Apher Sci 60(3):103096, 2021. e-Pub 2021. PMID: 33612449.
- Davila-Gonzalez D, Barrios-Ruiz A, Fountain E, Cheng L, Masarova L, Verstovsek S, Rojas-Hernandez CM. Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center. Clin Lymphoma Myeloma Leuk 21(4):224-229, 2021. e-Pub 2021. PMID: 33349602.
- Yan M, Kieser R, Wu CC, Qiao W, Rojas-Hernandez CM. Clinical Factors and Outcomes of Sub Segmental Pulmonary Embolism in Cancer Patients. Blood Adv 5(4):1050-1058, 2021. e-Pub 2021. PMID: 33599740.
- Rojas-Hernandez CM. Hypereosinophilia: An Unusual Bystander in Cancer. J Immunother Precis Oncol 4(1):26-27, 2021. e-Pub 2021. PMID: 35664824.
- Wilson NR, Khan M, Cox TM, Nassif M, Qiao W, Garg N, Aung FM, Oo TH, Rojas-Hernandez CM. Bleeding Outcomes in Thrombocytopenic Acute Leukemic Patients with Venous Thromboembolism. EJHaem 1(2):448-456, 2020. e-Pub 2020. PMID: 35845011.
- Alcedo PE, Garcia-Perdomo HA, Rojas-Hernandez CM. The Net Benefit of Thrombolysis in the Management of Intermediate Risk Pulmonary Embolism: Systematic Review and Meta-Analysis. EJHaem 1(2):457-466, 2020. e-Pub 2020. PMID: 35844995.
- Rojas-Hernandez CM, Tang VK, Sanchez-Petitto G, Qiao W, Richardson M, Escalante C. Development of a Clinical Prediction Tool for Cancer-associated Venous Thromboembolism (CAT): The MD Anderson Cancer Center CAT Model. Support Care Cancer 28(8):3755-3761, 2020. e-Pub 2020. PMID: 31828489.
- Wilson N, Rojas-Hernandez CM. Paraneoplastic Leukocytosis and Thrombocytosis Secondary to IL-6 Elevation in Metastatic Melanoma. EJHaem 1(1):249-250, 2020. e-Pub 2020. PMID: 35847732.
- Abdel-Wahab N, Tayar JH, Fa'ak F, Sharma G, Lopez-Olivo MA, Yousif A, Shagroni T, Al-Hawamdeh S, Rojas-Hernandez CM, Suarez-Almazor ME. Systematic Review of Observational Studies Reporting Antiphospholipid Antibodies in Patients with Solid Tumors. Blood Adv 4(8):1746-1755, 2020. e-Pub 2020. PMID: 32337583.
- Yang W, Tholpady A, Casteel KN, Rojas-Hernandez C. Platelet-Refractoriness and the Clinical Impact in Leukemia Population at a Metropolitan Academic Cancer Center. Leuk Lymphoma 61(4):1-3, 2020. e-Pub 2020. PMID: 31795873.
- Pabba K, Rojas-Hernandez CM. Concurrent Presentation of a Hemorrhagic Pericardial Effusion and Venous Thromboembolism in Malignancy: A Systematic Review of Case Studies. J Thromb Thrombolysis 48(3):454-458, 2019. e-Pub 2019. PMID: 31134447.
- Hasanov E, Fard EV, Puravath A, Johnston JS, Peerbhai S, Rojas-Hernandez CM. T-cell Large Granular Lymphocytic Leukemia in the Context of Rheumatoid Arthritis. Lancet 392(10152):1071, 2018. e-Pub 2018. PMID: 30264706.
- Hasanov M, Konoplev SN, Hernandez CMR. Nivolumab-Induced Cold Agglutinin Syndrome Successfully Treated with Rituximab. Blood Adv 2(15):1865-1868, 2018. e-Pub 2018. PMID: 30072374.
- Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, Garcia D, Grosso M, Kakkar AK, Mercuri MF, Middeldorp S, Hernandez CR, Santamaria A, Schwocho L, Segers A, Verhamme P, Wang TF, Weitz JI, Zhang G, Zwicker JI, Büller HR, Raskob GE. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost 118(8):1439-1449, 2018. e-Pub 2018. PMID: 30060256.
- Khan M, Cox TM, Nassif M, Alzubaidi MA, Garg N, Qiao W, Aung FM, Oo TH, Rojas-Hernandez CM. Comparative Outcomes of Thrombocytopenic Acute Leukemic Patients with Venous Thromboembolism at a Comprehensive Cancer Center. J Thromb Thrombolysis 45(3):377-385, 2018. e-Pub 2018. PMID: 29417408.
- Sun Y, Lee SK, Oo TH, Rojas-Hernandez CM. Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases. J Immunother 41(1):32-34, 2018. e-Pub 2018. PMID: 29111982.
- Patt Y, Rojas-Hernandez C, Fekrazad HM, Bansal P, Lee FC. Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20. Oncologist 22(10):1158-e116, 2017. e-Pub 2017. PMID: 28687627.
- Daver N, McClain K, Allen CE, Parikh SA, Otrock Z, Rojas-Hernandez C, Blechacz B, Wang S, Minkov M, Jordan MB, La Rosée P, Kantarjian HM. A Consensus Review on Malignancy-Associated Hemophagocytic Lymph Histiocytosis in Adults. Cancer 123(17):3229-3240, 2017. e-Pub 2017. PMID: 28621800.
- Wong M, Oo TH, Qiao W, Garg N, Rojas-Hernandez CM. Performance of 4T Score and Heparin-platelet Factor 4 Antibody in the Diagnosis of Heparin-induced Thrombocytopenia (HIT) in Cancer. J Thromb Thrombolysis 44(2):261-266, 2017. e-Pub 2017. PMID: 28677022.
- Hust MA, Blechacz BRA, Bonilla DL, Daver N, Rojas-Hernandez CM. Adult Sancer-related Hemophagocytic Lymphohistiocytosis: A Challenging Diagnosis - A Case Report. J Med Case Rep 11(1):172, 2017. e-Pub 2017. PMID: 28651636.
- Rojas-Hernandez CM, Nemunaitis J, Marjon KD, Bustamante D, Zhang QY, Gillette JM. Chronic Lymphocytic Leukemia with Clinical Debut as Neurological Involvement: A Rare Phenomenon and the Need for Better Predictive Markers. BMC Hematol 17(1):3, 2017. e-Pub 2017. PMID: 28174663.
- Hu S, Bansal P, Lynch D, Rojas Hernandez CM, Dayao Z. Rituximab, Etoposide, Methylprednisolone, High-dose Cytarabine, and Cisplatin in the Treatment of Secondary Hemophagocytic Lymphohistiocytosis with Classical Hodgkin Lymphoma: A Case Report and Review of the Literature. J Med Case Rep 10(1):365, 2016. e-Pub 2016. PMID: 27998299.
- Ko H, Maymani H, Rojas-Hernandez C. Hemolytic Uremic Syndrome Associated with Escherichia Eoli O157:H7 Infection in Older Adults: A Case Report and Review of the Literature. J Med Case Rep 10(1):175, 2016. e-Pub 2016. PMID: 27301547.
- Tang VK, Huh YO, Tayar JH, Rojas Hernandez CM. Primary Autoimmune Myelofibrosis as Etiology of Pancytopenia Mimicking Myelodysplastic Syndrome. Leuk Lymphoma 57(3):731-4, 2016. e-Pub 2016. PMID: 26422082.
- Sarwari NM, Khoury JD, Hernandez CM. Chronic Epstein Barr Virus Infection Leading to Classical Hodgkin Lymphoma. BMC Hematol 16(1):19, 2016. e-Pub 2016. PMID: 27437106.
- Rojas-Hernandez CM, Coleman JF, Czuchlewski DR, Fekrazad MH. Spontaneous Regression of High Grade Primary Gastric Lymphoma in an Untreated Viral Hepatitis Infection. Leuk Lymphoma 55(11):2643-5, 2014. e-Pub 2014. PMID: 24512317.
- Villegas SL, Ferro BE, Rojas CM, Perez-Velez CM. Assessment of Children Exposed to Adult Pulmonary Tuberculosis in Cali, Colombia. Paediatr Int Child Health 34(3):170-7, 2014. e-Pub 2014. PMID: 24939365.
- Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G, Kim SJ, Jindani A, Enarson DA, Nunn AJ, Trial Group SC. Efficacy and Safety of a 4-Drug Fixed-Dose Combination Regimen Compared with Separate Drugs for Treatment of Pulmonary Tuberculosis: The Study C Randomized Controlled Trial. JAMA 305(14):1415-23, 2011. e-Pub 2011. PMID: 21486974.
Review Articles
- Yikilmaz AS, Rojas Hernandez CM. A Rare But Fatal Toxicity: Immune Checkpoint Inhibitor–Related Acquired Thrombotic Thrombocytopenic Purpura. Journal of Immunotherapy and Precision Oncology 8(1):15-22, 2024. e-Pub 2024. PMID: 39811422.
- Arteaga, AM, Font, C, Rojas Hernandez, CM. Quality of life in oncological patients with venous thromboembolic disease. Research and Practice in Thrombosis and Haemostasis 8(5), 2024. e-Pub 2024. PMID: 39188888.
- Babakhanlou R, Verstovsek S, Pemmaraju N, Rojas-Hernandez CM. Secondary Erythrocytosis. Expert Rev Hematol 16(4):245-251, 2023. e-Pub 2023. PMID: 36927204.
- Madani M, Goldstein D, Stefanescu R, Woodman SE, Rojas-Hernandez CM. Characterization of Coagulopathy and Outcomes in Cancer Patients with Severe COVID -19 Illness: Longitudinal Changes in Hospitalized Cancer Patients. Cancer Med 11(20):3771-3785, 2022. e-Pub 2022. PMID: 35470980.
- Tsoukalas N, Brito-Dellan N, Font C, Butler T, Rojas-Hernandez CM, Butler T, Escalante C. Complexity and Clinical Significance of Drug-drug Interactions (DDIs) in Oncology: Challenging Issues in the Care of Patients Regarding Cancer-associated Thrombosis (CAT). Support Care Cancer 30(10):8559-8573, 2022. e-Pub 2022. PMID: 35932318.
- Rojas-Hernandez CM, Oo TH. Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials. Drugs 79(6):621-631, 2019. e-Pub 2019. PMID: 30905033.
- Rojas-Hernandez CM, Zapata-Copete JA, Garcia-Perdomo HA. Role of Vena Cava Filters for the Management of Cancer-related Venous Thromboembolism: Systematic Review and Meta-analysis. Crit Rev Oncol Hematol 130:44-50, 2018. e-Pub 2018. PMID: 30196911.
- Rojas-Hernandez CM. The Role of Direct Oral Anticoagulants in Cancer-related Venous Thromboembolism: A Perspective Beyond the Guidelines. Support Care Cancer 26(3):711-720, 2018. e-Pub 2018. PMID: 29188376.
- Rojas-Hernandez CM, Oo TH. The Unusual Nutritional and Toxin-related Underproduction Anemias: Approaching the Riddle Beyond Iron, Cobalamin, and Folate. Discov Med 25(136):67-74, 2018. e-Pub 2018. PMID: 29579413.
- Oo TH, Rojas-Hernandez CM. Challenging Clinical Presentations of Pernicious Anemia. Discov Med 24(131):107-115, 2017. e-Pub 2017. PMID: 28972879.
- Rojas Hernandez CM, Oo TH. Advances in Mechanisms, Diagnosis, and Treatment of Pernicious Anemia. Discov Med 19(104):159-68, 2015. e-Pub 2015. PMID: 25828519.
- Rojas-Hernandez CM, Garcia DA. The Novel Oral Anticoagulants. Semin Thromb Hemost 39(2):117-26, 2013. e-Pub 2013. PMID: 23390028.
Professional Educational Materials
- Rojas Hernandez CM, Chavarro Dominguez CA. Cancer en el Adult Mayor. Carta de la Salud Fundación Valle del Lili, 2018.
Other Articles
- Wilson NR, Lockhart JR, Garcia-Perdomo HA, Oo TH, Rojas-Hernandez CM Management and Outcomes of Hematological Immune-related Adverse Events: Systematic Review and Meta-analysis. J Immunother 45(1):13-24, 2022. PMID: 34469413.
- Rojas-Hernandez CM, Oo TH, Garcia-Perdomo HA Risk of Intracranial Hemorrhage Associated with Therapeutic Anticoagulation for Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-analysis. J Thromb Thrombolysis 43(2):233-240, 2017. PMID: 27704333.
Editorials
- Torres-Patino IC, Rojas-Hernandez CM, Garcia-Perdomo HA. Barriers to Access and Permanence at the University: A Point of View. Einstein (Sao Paulo) 19:eED6447, 2021. PMID: 34932778.
Abstracts
- Cortez, Torres Luna, Blancarte Ibarra, Riojas Suárez, Garcia-Perdomo, Rojas Hernandez. Risk of venous thromboembolism associated with CDK 4/6 inhibitors and adjuvant hormonal therapy in non-metastatic breast cancer: A systematic review and meta-analysis, 2025. e-Pub 2025.
- Subramanian NG, Aung FM, Patel K, Lee HC, Jin S, Young E, Rojas-Hernandez CM. Clinical Factors Associated to VTE in Multiple Myeloma Patients Treated with Daratumumab 140(Supplement 1):5177-5179, 2022. e-Pub 2022.
- Soto-Lanza F, Milton DR, Oo TH, Rojas-Hernandez CM. The Natural History of Heparin Induced Thrombocytopenia (HIT) in Cancer Patients 140(Supplement 1):5131-5132, 2022. e-Pub 2022.
- Avery J, Martens KL, Nguyen D, Basom R, Lee S, Garcia DA, Rojas-Hernandez CM, Li A. Utilization of Natural Language Processing in Venous Thromboembolism Identification. Blood 140(Supplement 1):7860-7861. e-Pub 2022.
- Li A, Martens KL, Nguyen D, Rondon G, Amos CI, Lee SJ, Basom R, Davis C, Garcia DA, Champlin RE, Shpall EJ, Rojas-Hernandez CM, Kebriaei P. Internal and External Validation of the High-2-Low Model: A Predictive Score for Venous Thromboembolism after Allogeneic Transplant. Blood 138:750, 2021. e-Pub 2021.
- Martens K, Amos C, Rojas Hernandez C, Kebriaei P, Basom R, Davis C, Kesten M, Carrier M, Garcia D, Lee S, Li A. Association of Anticoagulation Resumption and Repeat Imaging on Venous Thromboembolism Recurrence after Allogeneic Hematopoietic Cell Transplantation (HCT) 5(Supplement 1), 2021. e-Pub 2021.
- Martens K, Amos C, Rojas Hernandez C, Kebriaei P, Basom R, Davis C, Kesten M, Carrier M, Garcia D, Lee S, Li A. Anticoagulation Strategies during Conditioning-induced Thrombocytopenia in Hematopoietic Cell Transplant Patients with Venous Thromboembolism 5(Supplement 1), 2021. e-Pub 2021.
- Oo TH, Rojas Hernandez CM. Diagnostic Performance of Heparin-Platelet Factor 4 Antibodies in the Identification of Heparin-Induced Thrombocytopenia in Cancer Population 134(Supplement_1):4896-4896, 2019. e-Pub 2019.
- Alcedo P, Rojas-Hernandez CM, Garcia Perdomo HA. The Net Clinical Benefit of Thrombolysis in the Management of Submassive Pulmonary Embolism: Systematic Review and Meta-Analysis 134(Supplement_1):2440-2440, 2019. e-Pub 2019.
- Goswamy R, Tannembaum DJ, Aung F, Rojas-Hernandez C. Practice Patterns and Clinical Outcomes of Platelet Alloimmunization in a Comprehensive Cancer Center 134(Supplement_1):1170-1170, 2019. e-Pub 2019.
- Rojas-Hernandez CM, Oo TH. Natural History of Heparin-induced Thrombocytopenia (HIT) in Cancer: A Cohort Analysis of Thrombosis and Bleeding Outcomes 3(S1):631, 2019. e-Pub 2019.
- Fountain E, Cheng L, Verstovsek S, Rojas Hernandez C. Patterns of JAK2- V617F Testing and Predictive Value of Erythropoietin in Adult Erythrocytosis: Experience at a Comprehensive Cancer Center 3(S1):184, 2019. e-Pub 2019.
- Abelhad NI, Qiao W, Rojas Hernandez CM. Outcomes in the Secondary Prevention of Cerebral Venous Thrombosis in Cancer Only Population. Research and Practice in Thrombosis and Haemostasis 3(S1):818, 2019. e-Pub 2019.
- Yang W, Tholpady A, Casteel K, Rojas Hernandez CM. The Epidemiology and Management of Platelet Refractoriness at a Comprehensive Cancer Center. American journal of Hematology 93(9):E74-E75, 2018. e-Pub 2018.
- Hasanov M, Hasanov E, Rojas-Hernandez C. Bleeding Challenge in Waldenström Macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia 18(Supplement 1):S246-S247, 2018. e-Pub 2018.
- Butler T, Escalante C, Rojas-Hernandez C, Font C, Oo T. Development of International Guidelines and Education Resources for Cancer-Associated Thrombosis (CAT). Journal of Supportive Care in Cancer 6(Supplement 2):S310, 2018. e-Pub 2018.
- Yan MN, Wu C, Qiao W, Rojas-Hernandez C. Evaluation of Clinical and Radiological Factors Associated with Thrombosis Recurrence in Cancer Associated Sub Segmental Pulmonary Embolism 130(Supplement 1):4637, 2017. e-Pub 2017.
- Sanchez-Petitto G, Escalante CP, Richardson MN, Rojas-Hernandez C. Modified Khorana Models for Prediction of Cancer-Associated Venous Thromboembolism: An Exploratory Study 130(Supplement 1):4635, 2017. e-Pub 2017.
- Ko HC, Rojas-Hernandez C, Oo TH. Clinical Outcomes of Acquired Factor VIII Inhibitors in Cancer Population: A Systematic Review 130(Supplement 1):5639, 2017. e-Pub 2017.
- Tun AM, Myint ZW, Rojas-Hernandez C, Guevara E, Thein KZ, Oo TH. Vitamin B12 Deficiency-Related Pseudo-Thrombotic Microangiopathy Might be Misdiagnosed and Treated with Plasma Product Therapy: Review of the Literature and Analysis of the Reported Cases 130(Supplement 1):5576, 2017. e-Pub 2017.
- Jawed Y, Sheth R, Kuban J, Rojas Hernandez CM. When Catheter Thrombosis Mimics Malignant Cava Thrombosis: The Role of Endovascular Interventions. Chest 152(4):A491, 2017. e-Pub 2017.
- Oo TH, Rojas-Hernandez CM. When Cancer Patients are HIT: A Literature Review of Heparin-Induced. Research and Practice in Thrombosis and Haemostasis 1:1-1451, 2017. e-Pub 2017.
- Yan M, Wu CC, Qiao W, Rojas-Hernandez CM. Outcomes of Subsegmental Pulmonary Embolism (SSPE) in Cancer Population. Research and Practice in Thrombosis and Haemostasis 1:1-1451, 2017. e-Pub 2017.
- Tang VK, Escalante CP, Lam TP, Richardson MN, Hernandez CM. Performance of Khorana Score Models in Predicting Occurrence of Incidental Venous Thromboembolism (VTE) in Cancer. Research and Practice in Thrombosis and Haemostasis 1:1-1451, 2017. e-Pub 2017.
- Wong MP, Oo TH, Qiao W, Garg N, Rojas Hernandez CM. Performance of 4T score and HIT Antibody in the Diagnosis of Heparin-Induced Thrombocytopenia in Cancer Patients. American Journal of Clinical Pathology 146(Supplement 1):330, 2016. e-Pub 2016.
- Ross JA, Miller M, Rojas-Hernandez CM. Safe and Effective Use of Direct Oral Anticoagulants (DOAC) Versus Conventional Anticoagulation for the Treatment of Cancer-related Venous Thromboembolism. Thrombosis Research 140:S173-S174, 2016. e-Pub 2016.
- Routh JK, Rojas-Hernandez CM, Crookston KP, Koenig SC. Severe Vitamin B12 Deficiency Mimicking Thrombotic Thrombocytopenic Purpura. American Journal of Clinical Pathology 142(5):702, 2014. e-Pub 2014.
- Rojas Hernandez CM. Freeze-Dried Platelets Decrease Bleeding in Refractory Thrombocytopenic Patients with Hematological Malignancies. AABB.
Book Chapters
- Oo, TH, Rojas Hernandez, CM, Vega Vazquez, F. Immune Thrombocytopenic Purpura Post Immune Checkpoint Inhibitor Therapy, 235-239, 2025.
- Nelson, BE, Oo, TH, Rojas Hernandez, CM. Autoimmune Hemolytic Anemia Post Immune Checkpoint Inhibitors, 227-234, 2025.
- Nelson BE, Oo TH, Rojas Hernandez CM. Autoimmune Hemolytic Anemia Post Immune Checkpoint Inhibitors. In: Challenging Cases in Immunotherapy Related Organ Toxicities. Springer, Cham, 227-234, 2025.
- Oo TH, Vega F, Rojas Hernandez CM. Immune Thrombocytopenic Purpura Post Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities. Springer, Cham, 235-239, 2025.
- Oo TH, Rojas-Hernandez, CM. Hematology Chapter. In: Managing Immunotherapy Related Organ Toxicities: A Practical Guide. 1. Springer Cham, 322, 2022.
- Alcedo PE, Sanchez-Petitto G, Rojas-Hernandez C. Idiopathic Thrombocytopenic Purpura. In: The 5-Minute Clinical Consult. 27. Wolters Kluwer, 2019.
- Villegas MV, Kattan JN, Rojas CM. Infecciones Nosocomiales en la Unidad de Cuidados Intensivos. In: Cuidado Intensivo y Trauma. 2. Distribuna, 859-872, 2009.
Letters to the Editor
- Subramanian NG, Guffey D, Avery J, Garcia D, Basom R, Lee SJ, Klein K, Kebriaei P, Rondon G, Shpall E, Jin S, Young E, Rojas Hernandez CM, Li A. Clinical Factors Associated With Catheter-Related VTE in Patients Undergoing Hematopoietic Cell Transplantation: A Multi-Center Study. Am J Hematol 100: 1463-1466, 2025.
- Qiao W, Young E, Feng C, Liu S, Jin J, Noor L, Rojas Hernandez CM, Borthakur G, Gorlova O, Afshar-Kharghan V. Association Between Abnormal Lipid Profile and Inflammation and Progression of Myelodysplastic Syndrome to Acute Leukemia. Exp Hematol Oncol 11: 58, 2022.
- Qdaisat A, Soud RA, Wu CC, Rojas Hernandez CM, Li J, Meng QH, Abdel-Razeq H, Yeung SJ. Poor Performance of D-dimer in Excluding Venous Thromboembolism Among Patients with Lymphoma and Leukemia. Haematologica 104: e265-e268, 2019.
- Ross JA, Miller MM, Rojas Hernandez CM. Comparative Effectiveness and Safety of Direct Oral Anticoagulants (DOACs) Versus Conventional Anticoagulation for the Treatment of Cancer-related Venous Thromboembolism: A Retrospective Analysis. Thromb Res 150: 86-89, 2017.
- Rojas-Hernandez CM, Oo TH, Garcia-Perdomo HA. A Meta-analysis of Intracranial Hemorrhage in Patients with Brain Tumors Receiving Therapeutic Anticoagulation. J Thromb Haemost 14: 2080-2081, 2016.
Patient Reviews
CV information above last modified March 06, 2026